- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 457/04 - Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula: , e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
Patent holdings for IPC class C07D 457/04
Total number of patents in this class: 29
10-year publication summary
|
1
|
0
|
1
|
2
|
3
|
3
|
6
|
2
|
3
|
0
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Idemitsu Kosan Co., Ltd. | 4219 |
3 |
| GATC Health Corp | 28 |
3 |
| Florida State University Research Foundation, Inc. | 822 |
2 |
| MAP Pharmaceuticals, Inc. | 50 |
2 |
| Regents of the University of Minnesota | 2768 |
2 |
| Theaprin Pharmaceuticals Inc. | 32 |
2 |
| Satsuma Pharmaceuticals, Inc. | 9 |
2 |
| The Royal Institution for The Advancement of Learning / McGill University | 713 |
2 |
| Terran Biosciences, Inc. | 103 |
2 |
| Novartis AG | 10345 |
1 |
| Sandoz AG | 1403 |
1 |
| The Regents of the University of California | 20556 |
1 |
| Agfa Healthcare | 149 |
1 |
| Duquesne University of the Holy Spirit | 126 |
1 |
| Lek Pharmaceuticals d.d. | 189 |
1 |
| T2pharma GmbH | 13 |
1 |
| HAVN Life Sciences Inc. | 5 |
1 |
| Cora Nutraceuticals Inc. | 1 |
1 |
| Other owners | 0 |